NEW YORK, NY / ACCESS Newswire / August 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has […]
NEW YORK, NY / ACCESS Newswire / August 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Informatica Inc. ("Informatica Inc.") (NYSE:INFA) concerning possible violations of federal securities laws. On February 13, 2025, Informatica issued a press release announcing its fourth quarter 2024 financial results, missing revenue forecasts and
NEW YORK, NY / ACCESS Newswire / August 15, 2025 / Levi & Korsinsky, LLP releases a Podcast regarding Sarepta Therapeutics, Inc. (NASDAQ:SRPT) class action securities lawsuit A Class Action lawsuit was filed on behalf of Sarepta Therapeutics, Inc. investors who lost money as a result of alleged securities fraud between June 22, 2023 and
NEW YORK, NY / ACCESS Newswire / August 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Snap Inc. ("Snap Inc.") (NYSE:SNAP) concerning possible violations of federal securities laws. Investors.com reported on August 6, 2025, that "Snap . . . stock tumbled Wednesday after the Snapchat parent company posted
NEW YORK, NY / ACCESS Newswire / August 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Thomson Reuters Corporation ("Thomson Reuters Corporation") (NASDAQ:TRI) concerning possible violations of federal securities laws. On August 6, 2025, Thomson Reuters published a press release reporting the Company’s second quarter 2025 results. During
NEW YORK, NY / ACCESS Newswire / August 15, 2025 / If you suffered a loss on your Sarepta Therapeutics, Inc. (NASDAQ:SRPT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sarepta-lawsuit-submission-form?prid=161604&wire=1&utm_campaign=16 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or
NEW YORK, NY / ACCESS Newswire / August 15, 2025 / If you suffered a loss on your Neogen Corporation (NASDAQ:NEOG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neogen-corporation-lawsuit-submission-form?prid=161603&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call
Results Highlights: – Revenue reached US$83.6 million, a year-on-year increase of 5.9%.– Sales volume reached 919,000 units, of which 779,000 units were proprietary products, representing a year-on-year increase of 8.6%.– Profit attributable to owners of the company increased by 5.1% year-on-year to US$19.8 million.– Core operating profit amounted to US$15.1 million, an increase of 11.4%
NEW YORK, NY / ACCESS Newswire / August 15, 2025 / If you suffered a loss on your Fiserv, Inc. (NYSE:FI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fiserv-inc-lawsuit-submission-form?prid=161601&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call
NEW YORK, NY / ACCESS Newswire / August 15, 2025 / If you suffered a loss on your Alto Neuroscience, Inc. (NYSE:ANRO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/alto-neuroscience-inc-lawsuit-submission-form?prid=161602&wire=1&utm_campaign=31 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or